Introduction {#Sec1}
============

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that afflicts about 1 in 50,000 people each year and involves loss of upper and lower motor neurons \[[@CR1]\]. Death typically follows 2 to 3 years after first onset. About 95% of cases are sporadic, while the rest have a family history of the disease. ALS also has overlapping clinical presentations with frontotemporal lobar degeneration (FTLD) and its most common subtype frontotemporal dementia (FTD), a neurological condition affecting the frontal and temporal lobes and marked by cognitive and behavioral impairment \[[@CR2]\]. About 20% of ALS patients also exhibit FTLD, and ALS and FTLD have been considered to be part of a continuous disease spectrum \[[@CR3]\].

A pathogenic GGGCCC hexanucleotide expansion in the first intron/promoter region of the *C9orf72* gene is the most common mutation associated with both ALS (∼11% of all cases) and FTLD/FTD (∼13%) \[[@CR3]--[@CR6]\]. Three possible non-exclusive mechanisms have been proposed by which the *C9orf72* repeat expansion may cause ALS-FTD: 1) haploinsufficiency and loss of C9orf72 protein function, 2) repeat-associated non-AUG (RAN) translation of the hexanucleotide repeats generating dipeptide repeats that aggregate in toxic neuronal cytoplasmic and nuclear aggregates, and 3) toxic gain-of-function from repeat-containing RNA which forms nuclear foci that sequester hexanucleotode repeat-binding proteins (reviewed in \[[@CR7]--[@CR10]\]). While most studies have focused on increasedtoxicity, accumulating evidence argues that a loss-of-function mechanism may also contribute to neurodegeneration. Consistently, various studies have reported a reduction in *C9orf72* mRNA and/or protein expression in brain and induced pluripotent stem cell (iPSC)-derived neuronal lines of some *C9orf72* ALS (C9ALS) and FTD patients \[[@CR4]--[@CR6], [@CR11]--[@CR25]\].

A series of studies have shown that the long isoform of human C9orf72 protein forms a complex with SMCR8 (Smith-Magenis Syndrome Chromosome Region, Candidate 8) and WDR41 (WD Repeat domain 41) proteins \[[@CR22], [@CR26]--[@CR35]\]. The *SMCR8* gene is within the deleted region of chromosome 17 associated with Smith-Magenis Syndrome (SMS), a developmental disorder of children involving intellectual disability, distinctive facial features, and behavioral problems, but no reported motor defects \[[@CR36], [@CR37]\]. WDR41 is a member of the WD-repeat family of proteins that act as protein-protein or protein-DNA interaction scaffolds for a variety of cellular functions \[[@CR38]\]. SNPs within the *WDR41* gene region have been associated with human caudate volume \[[@CR39]\].

Bioinformatic analyses first identified both C9orf72 and SMCR8 proteins as having DENN (Differentially Expressed in Normal and Neoplastic cells) domains that are present in guanine nucleotide exchange factors (GEFs) for Rabs, multi-functional small GTPases involved in intracellular membrane trafficking and fusion, vesicle formation and transport, and autophagy \[[@CR40]--[@CR42]\]. The autolysomal-autophagy pathway involves generation of the autophagosome, an organelle surrounded by a double lipid bilayer. Autophagosomes engulf cytoplasmic components, such as protein aggregates, damaged organelles, and foreign pathogens, and fuse with lysosomes to generate autolysosomes that mediate degradation of the cargo. Autophagosomes also fuse with endosomes, forming an intermediate organelle called the amphisome, before fusion with lysosomes. Various studies have linked wild-type C9orf72 protein with proteostasis, showing that, in complex with SMCR8 and WDR41, it bind Rabs and plays roles in autophagy and initiation of autophagosome formation, as well as being linked by function and colocalization to endocytosis and lysosomal and endosomal trafficking (\[[@CR9], [@CR21]--[@CR23], [@CR26], [@CR28], [@CR29], [@CR31], [@CR32], [@CR34], [@CR43]--[@CR48]\], and Discussion for review). A role in the endo-lysosome pathway has also been shown for the *C. elegans C9orf72* ortholog *alfa-1* \[[@CR49]\]. Aoki et al. \[[@CR46]\] linked the interaction of C9orf72 and RAB7L1 with regulation of vesicle trafficking, and WDR41 is necessary for recruitment of the C9orf72 complex to lysosomes \[[@CR35], [@CR50]\]. Thus, C9orf72 is a regulator of cellular proteostasis.

Additional roles for the C9orf72 complex have also been reported. C9orf72 alters phosporylation of cofilin and activates the small GTPase ADP-ribosylation factor-1/2 (ARF1/2) involved in actin dynamics \[[@CR51]\]. Altered C9orf72 protein levels also causes changes in glutamatergic receptor levels, glutamate cycling and endothelin signaling, and excitotoxicity in response to glutamate, as well as widespread transcriptional changes \[[@CR21], [@CR52]--[@CR54]\]. However, the consequences of loss of C9orf72 protein for motor neuron function remain unclear. In vivo, diminished motor function and axonal degeneration of motor neurons have been reported in zebrafish and *C. elegans* depleted of C9orf72 \[[@CR55], [@CR56]\]. However, subsequent studies detected no or only mild motor function defects in mice deficient for murine C9orf72 ortholog 3110043O21Rik \[[@CR45]\]. On the other hand, in a gain-of-function C9ALS/FTD mouse model, Shao et al. \[[@CR57]\] found that 3110043O21Rik haploinsufficiency or loss was associated with increased motor behavior deficits in a dose-dependent manner, while Liang et al. \[[@CR25]\] reported that Smcr8 knockout (KO) mice displayed motor behavior defects and axonal swelling. While effects on motor function are uncertain, immune system pathology, spleen and lymph node enlargement, defects in macrophage, myeloid and microglial cell function, altered lysosomal trafficking, and decreased body weight and survival have all been reported for *C9orf72* or *SMCR8* knockout mice \[[@CR21], [@CR28], [@CR32], [@CR45], [@CR58]--[@CR65]\]. Despite these findings, so far no pathogenic loss-of-function coding mutation in *C9orf72*, *SMCR8* or *WDR41* genes has been found \[[@CR66]\].

To increase understanding of the diverse functions of the C9orf72-SMCR8-WDR41 complex, we sought to determine by mass spectroscopy (MS) analyses the interactome composition of the SMCR8 component. Notably, we found that the SMCR8 complex includes numerous ubiquitin-related proteins and products of genes associated with numerous Mendelian neurological disorders. MS analyses, co-IP experiments, and association of SMCR8 with cytoplasmic stress granules (SGs) in cultured cells support a link between SMCR8 and the ubiquitin pathway. Furthermore, we reinforce previous observations that SMCR8 and C9orf72 protein levels are positively linked, now showing in vivo that SMCR8 might prove to be a useful biomarker for the C9orf72 expansion mutation in ALS patients.

Materials and methods {#Sec2}
=====================

Plasmid constructs {#Sec3}
------------------

Ultimate ORF cDNA clones (Invitrogen), with V5-epitope tags and tobacco etch virus (TEV) protease cleavage sites on their N-termini, were recloned by shuttling them from pENTR221 vector into pcDNA3.1/nV5-DEST using Gateway Technology (Invitrogen). Ultimate ORF Clones included AIFM1 (clone identifier IOH61019), BAG5 (IOH26366), C9orf72 (IOH45695), DARS (IOH4209), DCTN1 (IOH42830), DDB1 (IOH13816), DNAJC7 (IOH14566), FKBP5 (IOH13816), G3BP1 (IOH7337), GTF2I (IOH62625), HSPB1 (IOH10530), MAGED2 (IOH3451), PARK7 (IOH3149), PPP2R1A (IOH13670), PSMA7 (IOH5011), PSMC5 (IOH3508), PSMD14 (IOH40112), QARS (IOH3529), RAB1A (IOH2921), RAB7A (IOH40569), RAB11A (IOH13764), RANGAP1 (IOH13287), RO60 (IOH22411), RNF40 (IOH6599), RUVBL2 (IOH3426), SLC25A6 (IOH5815), SQSTM1 (IOH5103), STIP1 (IOH5061), STUB1 (IOH56981), SUGT1 (IOH2955), and TBK1 (IOH21006).

Clones purchased or obtained as gifts included FLAG-UBR5 (pCMV-Tag2B EDD; Addgene plasmid \#37188 \[[@CR67]\]), pcDNA5 FRT/TO FLAG-SMCR8 (FL-SMCR8), pcDNA5 FRT/TO HA-SMCR8, and pcDNA5 FRT/TO GFP SMCR8 (MRC PPU Reagents and Services, University of Dundee), GFP-(GA)~50~ (L. Petrucelli, Mayo Clinic, Florida, \[[@CR68]\]) pRK5-myc-TDP-43 (J. Wang, Johns Hopkins University, \[[@CR69]\]), mRFP-UBB (Addgene plasmid \#11935, \[[@CR70]\]), HA-UBB (V. Dawson, Johns Hopkins University, \[[@CR71]\]), and pDest51-USP9X-V5 (R. Hughes, Buck Institute for Research on Aging, \[[@CR72]\]). FL-UBB was generated using Ultimate ORF Clone IOH56688 and modified Gateway vector pEZYflag (Addgene plasmid \#18700, Y.-Z. Zhang). C9orf72-FL, RO60-FL, SMCR8-V5, and WDR41-FL constructs were generated by PCR-amplification of Ultimate ORF cDNA clones, using a primer with AAG linker and C-terminal FLAG- or V5-tag, and cloning of the products in pcDNA6/myc-His B (pcDNA6, Invitrogen).

Cell line and tissue samples {#Sec4}
----------------------------

Human embryonal carcinoma 2102Ep (a gift from P.K. Andrews, University of Sheffield, UK) and nTERA2D1 cells, human cervical cancer HeLa-JVM cells \[[@CR73]\], human embryonic kidney (HEK) 293T cells (ATCC), human neuroblastoma SH-SY-5Y cells (ATCC CRL-2266), and mouse neuroblastoma Neuro2A cells (a gift from D. Hackam, JHU) were grown in Dulbecco's modified Eagle's Medium. Mouse hybrid spinal cord neuron/neuroblastoma NSC-34 cells (a gift from D. Griffen, JHU) and human neuroblastoma SK-N-SH cells (a parental line of SH-SY-5Y cells; gifts of D. Valle, JHU) were grown in Eagle's Minimum Essential Medium. Medium was supplemented with 10% FBS (Hyclone), GlutaMax, and Pen-Strep (Invitrogen). Plasmid transfections used FuGENE HD (Promega) reagent. As necessary, cells were treated with 20 μM MG-132 proteasome inhibitor (Cell Signaling) for about 20 h to inhibit protein degradation, or with 0.25 mM sodium arsenite (NaAsO~2~) or 3 mM dithiothreitol (DTT, Sigma) for 80 min and 2 h, respectively, to induce cytoplasmic SGs.

Post-mortem ALS spinal cord and unaffected control brain motor cortex tissues were obtained from Drs. J. Ravits and R. Batra of the Department of Neurosciences, University of California San Diego School of Medicine \[[@CR74]\], and C9ALS and unaffected control samples were from the Target ALS Multicenter Postmortem Tissue Core (Table [S4](#MOESM1){ref-type="media"}). C9ALS samples had been confirmed for the C9orf72 expansion using repeat-primed PCR (RP-PCR) and Illumina Expansion Hunter (M. Harms, Columbia University, pers. comm.). Frozen spinal cord tissues were obtained from the University of Maryland Brain and Tissue Bank of the NIH NeuroBioBank. Frozen C9ALS and unaffected control cerebrospinal fluid (CSF) samples were from the Northeast ALS Consortium (NEALS). CSF was resuspended directly in 3X SDS loading buffer or first concentrated by tricholoracetic acid precipitation, and then analyzed by Western blotting using α-SMCR8 antibodies. Up to 20 μg of CSF total protein were loaded per well.

Protein isolation and immunoprecipitation {#Sec5}
-----------------------------------------

For MS sequence determination, HEK 293T cells in T~75~ flasks were transfected using FuGENE HD (Promega) with 15 μg of FL-SMCR8, C9orf72-FL, or pcDNA6/myc-His B empty vector and expanded for approximately 45 h, followed by whole cell lysate preparation by sonication using a Diagenode Bioruptor. IP and sample recovery were as previously described \[[@CR75], [@CR76]\]. Treatment of samples with 25 μg/ml DNase-free RNase (Roche) and 25 μg/ml RNaseA (Qiagen) was conducted in the absence of RNase inhibitors.

For other protein extracts, tissues or cells were lysed in RIPA buffer (Sigma) with Mammalian Protease Inhibitor Cocktail and phenylmethanesulfonyl fluoride (Sigma) and homogenized by Diagenode Bioruptor. For tissues, 2 mm ziconium silicate beads (Next Advance, Inc.) were added to the tubes. Supernatants were recovered by centrifugation at 11K rpm at 4 °C for 15 min and resuspended in 3X SDS loading buffer.

For each interaction co-IP (Fig. [2](#Fig2){ref-type="fig"}), extracts from approximately 5 × 10^6^ 293T cells in T~75~ flasks transfected with tagged SMCR8 and test protein constructs were prepared in 700 μl of lysis buffer (160 mM NaCl, 50 mM Tris, 1 mM EDTA, 0.25% NP40) containing protease and phosphatase inhibitors (Sigma), and RNasin (Qiagen) and vanadyl ribonucleoside complexes (Sigma) as required, and immunoprecipitated as previously described \[[@CR75], [@CR76]\].

Antibody analyses {#Sec6}
-----------------

Commercial antibodies included mouse (ms) α-V5-tag (Invitrogen), rabbit (rb) α-DYKDDDDK-tag (α-FLAG) (D6W5B), ms α-HA-tag (6E2), rb α-Myc-tag (71D10), rb α-HSP90, and ms α-Ubiquitin (UBB) (P4D1) (Cell Signaling Technology), rb α-4E-T, rb α-C9orf72 (S-14), goat (gt) α-eIF3η (N-20), ms α-p70 S6 kinase (which recognizes HEDLS/EDC4 \[[@CR77]\]), gt α-TIA1 (C-20), and rb α-WDR41 (S-12) (Santa Cruz Biotechnology), rb α-SMCR8 (ab186504, epitope region 841--890) and rb α-SMCR8 (ab202283, epitope region 600--650) (Abcam), rb α-C9orf72 (22637--1-AP), rb α-SMCR8 (21125--1-AP, epitope region 588--937), and rb α-WDR41 (26817--1-AP) (Proteintech), and rb α-SMCR8 (A304-694A, epitope region 600--650) (Bethyl). Monoclonal ms α-4H1-ORF1 was kindly provided by Dr. K. Burns (JHU, USA, also Millipore MABC1152, \[[@CR78]\]), rb α-C9-L and rb α-C9-S antibodies by Dr. J. Robertson (U. Toronto, Canada, \[[@CR19], [@CR79]\]), and α-GW182 human serum (IC-6) by Dr. M. Fritzler (U. Calgary, \[[@CR80]\]). Donkey Cy3-, DyLight 488-, or DyLight 549-conjugated, and HRP-conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories.

Western blotting, immunofluorescence (IF) microscopy, and fluorescent in situ hybridization (FISH) were performed as described \[[@CR81], [@CR82]\]. All Western blotting used NuPAGE 4--12% Bis-Tris gels and MOPS buffer, except brain tissue analyses of Fig. [5](#Fig5){ref-type="fig"}b,c which used NuPAGE 3--8% Tris-acetate gels (Thermo Fisher). Detection used Supersignal West Pico or West Pico Plus Chemiluminescent Substrate (Thermo Fisher) with ECL Hyperfilm (MilliporeSigma).

Immunostained cells were examined using a Nikon Eclipse Ti-A1 confocal microscope with NIS-Elements AR software.

MS sequencing and data analyses {#Sec7}
-------------------------------

MS sequencing and database analyses was performed by the Johns Hopkins Mass Spectrometry and Proteomics Facility as previously described \[[@CR75], [@CR76]\]. Peptide sequences were identified using Proteome Discoverer and Mascot software (Matrix Science) to search the NCBInr 167 database, including gly-gly modifiation on lysine as a variable protein modification. False discovery rate (FDR) was set at 1.0. Mascot search result \*.dat files were processed in Scaffold (Proteome Software, Inc.) to validate protein and peptide identifications. Exclusion criteria for proteins are described in the Results section.

Functional analyses of gene lists obtained by MS sequencing utilized DAVID v6.7 (Database for Annotation, Visualization and Integrated Discovery \[[@CR83]\]). Protein multiple alignments used Clustal Omega 1.2.1 (EMBL-EBI) and the ESPript 3.0 web sever (<http://espript.ibcp.fr/ESPript/ESPript/>). RNA-Seq datasets from public databases (GEO GSE67196 and NeuroLINCS dbGaP Study phs001231 SRP098831) were analyzed for gene expression using the software package TETranscripts as previously described \[[@CR84], [@CR85]\]. Ubiquitination prediction algorithms included UbPred (<http://www.ubpred.org>, \[[@CR86]\]), BDM-PUB (<http://bdmpub.biocuckoo.org>), and UbiSite (<http://csb.cse.yzu.edu.tw/UbiSite/>).

Results {#Sec8}
=======

Confirmation of the SMCR8-C9orf72-WDR41 complex and detection using commercial antibodies {#Sec9}
-----------------------------------------------------------------------------------------

Previous studies characterizing the C9orf72 proteome identified a complex consisting of the proteins C9orf72, SMCR8 and WDR41 \[[@CR22], [@CR26]--[@CR35]\]. By means of co-immunoprecipitation (co-IP) and MS sequencing, here we sought to identify proteins that associate with SMCR8. First, we confirmed that C9orf72, SMCR8 and WDR41 proteins formed a stable complex in our overexpression experimental system using human embryonic kidney (HEK) 293T cells. Consistent with previous reports, even in the presence of RNase, epitope-tagged SMCR8 and C9orf72 co-IPed C9orf72 and SMCR8 proteins, respectively (Fig. [1](#Fig1){ref-type="fig"}a, b). Furthermore, we confirmed that FLAG-tagged WDR41 interacts with endogenous C9orf72 and SMCR8 (Fig. [1](#Fig1){ref-type="fig"}c). Fig. 1Protein interaction analyses by Western blotting and co-IP of the SMCR8 complex in HEK 293T cells (see Fig. [S1](#MOESM1){ref-type="media"} for antibody analyses). **a** Endogenous C9-L (arrow) co-IPs with FLAG-tagged SMCR8. The thick arrowhead marks a band consistent in size with C9-S. **b** FLAG-tagged C9orf72 co-IPs both endogenous and co-transfected HA-tagged SMCR8. **c** FLAG-tagged WDR41 protein co-IPs both endogenous C9orf72 and SMCR8 proteins (indicated by arrows). Tagged C9orf72 and WDR41 proteins of (**b**) and (**c**) are not visible in whole cell lysates at the Western blot film exposure times shown. **d** C9orf72-FL, FL-SMCR8, and empty vector were immunoprecipitated on α-FLAG agarose from transfected 293T whole cell lysates, resolved on a polyacrylamide gel, and silver-stained. IP reactions were in the presence or absence of 50 μg/ml RNases. Complex immunoprecipitate samples were analyzed by MS sequencing. Arrows indicate full-length protein bands. Protein molecular weight markers are those of Novex Sharp Pre-stained Protein Standard (Thermo Fisher Scientific)

We next assessed the efficacy of several commercial antibodies against these proteins. Human *C9orf72* expresses a 54-kilodalton (kD) long protein isoform (C9-L) and a 25-kD short isoform (C9-S). It has been noted that commercial C9orf72 antibodies often detect additional bands other than C9-L or fail to detect C9-S \[[@CR17], [@CR19], [@CR23]\]. Consistent with this observation, the Santa Cruz S-14 antibody (α-C9orf72-SC) detected multiple bands in whole cell lysates as well as products of size consistent with both endogenous C9-L and C9-S; only C9-L co-IPed with tagged SMCR8 or WDR41 (Fig. [1](#Fig1){ref-type="fig"}a,c). Similarly, in both cultured cells and brain and spinal cord tissue lysates, the Proteintech 22,637--1-AP antibody (α-C9orf72-PT) marked a major band consistent with C9-L (arrow), plus additional products (Fig. [S1](#MOESM1){ref-type="media"}A). A small number of non-commercial C9orf72-specific antibodies have also been described \[[@CR17], [@CR23], [@CR30], [@CR79]\].

Both mouse and human SMCR8 have two predicted isoforms, the full length 105-kD protein and a C-terminal truncated 87.4-kD isoform generated by alternate splicing \[[@CR36]\]. Our search of GenBank revealed additional human *SMRC8* mRNA isoforms potentially encoding 35.9-kD (accession numbers BC001018, BC005067), 75.2-kD (AK296847.1), and 93-kD (BC101116, BC101117) protein products. Tissue-specific transcripts of various sizes have also been experimentally observed for human *SMCR8* \[[@CR36]\]. The Proteintech, Bethyl (A304-694A), and Abcam (ab186504 and ab202283) α-SMCR8 antibodies all marked a band consistent in size with full-length SMCR8 (i.e. 105 kD, arrows in Fig. [S1](#MOESM1){ref-type="media"}B-E), plus additional bands of unknown specificicy, but which could in part relate to the above desribed SMCR8 protein isoforms. The Bethyl and Abcam ab202283 α-SMCR8 antibodies have been used in other studies, and our observations are similar \[[@CR34], [@CR50], [@CR65], [@CR79]\]. Interestingly, although expression of full length SMCR8 protein was detected in human brain tissues, none was seen in spinal cord tissue lysates of multiple samples (Fig. [S1](#MOESM1){ref-type="media"}B-E).

WDR41 has two predicted isoforms of 51.7 and 45.5 kD (Swiss Prot. Q9HAD4--1, Q9HAD4--2). For selected cancer cell lines, both the Santa Cruz (S-12) and Proteintech (26817--1-AP) polyclonal antibodies detected doublet bands consistent in size with these isoforms (Fig. [S1](#MOESM1){ref-type="media"}F, G). These bands were very faint (Proteintech) or absent (Santa Cruz) from human brain and spinal cord tissue lysates, although bands of larger and smaller sizes were visible by Western blotting of cultured cells.

SMCR8 interactome contains many central nervous system (CNS) disease proteins {#Sec10}
-----------------------------------------------------------------------------

Because of the possible non-specific protein interactions described above, we considered commercial antibodies unsuitable for co-IP interactome studies. Therefore, we exploited a co-IP/MS protocol that we have successfully used in previous studies \[[@CR75], [@CR76]\]. We transfected C9-L with C-terminal FLAG (FL)-tag, full-length SMCR8 with N-terminal FLAG-tag, or empty vector control in HEK 293T cells and performed α-FLAG IP from whole cell extracts in the presence or absence of RNase (Fig. [1](#Fig1){ref-type="fig"}d). Complex immunoprecipitated samples were analyzed by liquid chromatography tandem MS. After excluding ribosomal proteins and likely contaminants (such as keratins), 340 and 201 proteins having three or more spectra and not detected in vector only control cell lysates were associated with FL-SMCR8 and C9-L-FL, respectively (Tables [1](#Tab1){ref-type="table"}, [S1](#MOESM1){ref-type="media"}, [S2](#MOESM1){ref-type="media"}). Furthermore, 71 proteins were found in both proteomes, although it should be noted that C9-L-FL was expressed at significantly lower levels than FL-SMCR8 (Fig. [1](#Fig1){ref-type="fig"}d), as previously reported \[[@CR29]\]. Tables [S1](#MOESM1){ref-type="media"} and [S2](#MOESM1){ref-type="media"} also note interacting partners of C9orf72 or SMCR8 proteins reported in previous studies \[[@CR19], [@CR28], [@CR29], [@CR31], [@CR32], [@CR34], [@CR51], [@CR87], [@CR88]\]. During the course of our investigations, another MS experiment was published that listed 1532 proteins that co-IPed with HA-tagged SMCR8 from 293T cells \[[@CR34]\], and a total of 272 of these (80%) were also present in our dataset (Table [S2](#MOESM1){ref-type="media"}). Table 1Summary of the C9orf72 and SMCR8 protein interactomes and selected functional categoriesGene NameProtein NameTotal \# SpectraRNase-+**A. C9orf72-FL** C9orf72chromosome 9 open reading frame 72108103**TOP 20 C9orf72-INTERACTING PROTEINS**  SMCR8Smith-Magenis syndrome chromosome region, candidate 8165217  WDR41WD repeat domain 416985  FLG2filaggrin family member 2336  LRPPRCleucine rich pentatricopeptide repeat containing2325  IARSisoleucyl-tRNA synthetase2122  SERPINB3serpin family B member 3210  CALML5calmodulin like 5200  HADHAhydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase, alpha subunit1814  CDSNcorneodesmosin178  EEF2eukaryotic translation elongation factor 21518  FABP5fatty acid binding protein 5150  COPB1coatomer protein complex subunit beta 11414  DSC1desmocollin 11415  U2AF2U2 small nuclear RNA auxiliary factor 2146  LUC7L3LUC7 like 3 pre-mRNA splicing factor134  EIF2S3eukaryotic translation initiation factor 2 subunit gamma1210  HNRNPH2heterogeneous nuclear ribonucleoprotein H2129  KHDRBS1KH RNA binding domain containing, signal transduction associated 1126  PSMC2proteasome 26S subunit, ATPase 21225**B. FL-SMCR8** SMCR8Smith-Magenis syndrome chromosome region, candidate 811351182**TOP 25 SMCR8-INTERACTING PROTEINS**  DNAJA1DnaJ heat shock protein family member A17076  GTF2Igeneral transcription factor IIi5561  CADcarbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase6248  ATP1A1ATPase Na+/K+ transporting subunit alpha 13846  EPRSglutamyl-prolyl-tRNA synthetase3640  MAGED1MAGE family member D12633  WDR41WD repeat domain 413233  DNAJC7DnaJ heat shock protein family member C73032  SLC25A3solute carrier family 25 member 32232  STUB1STIP1 homology and U-box containing protein 13031  GCN1GCN1, eIF2 alpha kinase activator homolog3730  DDB1damage specific DNA binding protein 13129  DYNC1H1dynein cytoplasmic 1 heavy chain 13829  CHD4chromodomain helicase DNA binding protein 41328  SLC25A11solute carrier family 25 member 111428  RANBP2RAN binding protein 22925  RUVBL2RuvB like AAA ATPase 23025  ATP2A2ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 21922  DNAJA3DnaJ heat shock protein family member A31922  IARSisoleucyl-tRNA synthetase1822  STIP1stress induced phosphoprotein 13722  COPAcoatomer protein complex subunit alpha2320  HUWE1HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase2920  AIFM1apoptosis inducing factor, mitochondria associated 11818  C9orf72chromosome 9 open reading frame 721518**AMINOACYL-tRNA SYNTHESIS**  EPRSglutamyl-prolyl-tRNA synthetase4013  IARSisoleucyl-tRNA synthetase1822  DARSaspartyl-tRNA synthetase118  MARSmethionyl-tRNA synthetase106  RARSarginyl-tRNA synthetase98  LARSleucyl-tRNA synthetase914  QARSglutaminyl-tRNA synthetase87  TARS2threonyl-tRNA synthetase 2, mitochondrial (putative)64  TARSthreonyl-tRNA synthetase40  FARSAphenylalanyl-tRNA synthetase alpha subunit06**CELL CYCLE**  SMC3structural maintenance of chromosomes 3128  CDK4cyclin dependent kinase 450  PCNAproliferating cell nuclear antigen54  MCM7minichromosome maintenance complex component 746  YWHAZtyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta49  RAD21RAD21 cohesin complex component30  CDC7cell division cycle 730  PLK1polo like kinase 139  PPP6Cprotein phosphatase 6 catalytic subunit30  CDKN2Acyclin dependent kinase inhibitor 2A03  MCM2minichromosome maintenance complex component 204  MCM5minichromosome maintenance complex component 504  SMC1Astructural maintenance of chromosomes 1A04**HEAT SHOCK PROTEINS / CHAPERONES**  DNAJA1DnaJ heat shock protein family member A17076  DNAJC7DnaJ heat shock protein family member C73032  DNAJA3DnaJ heat shock protein family member A31922  DNAJA3DnaJ heat shock protein family member A31922  HSPH1heat shock protein family H member 1198  BAG5BCL2 associated athanogene 51811  DNAJA2DnaJ heat shock protein family member A21516  BAG2BCL2 associated athanogene 21116  BAG6BCL2 associated athanogene 6118  SERPINH1serpin family H member 1110  HSPB1heat shock protein family B member 1109  MDN1midasin AAA ATPase 11014  FKBP8FK506 binding protein 880  DNAJB6DnaJ heat shock protein family member B664  PFDN2prefoldin subunit 254  DNAJB1DnaJ heat shock protein family member B140  HSPA4heat shock protein family A member 443  HSPA4heat shock protein family A member 443  RBBP7RB binding protein 7, chromatin remodeling factor34  SERPINB3serpin family B member 330  BAG3BCL2 associated athanogene 323  UNC45Aunc-45 myosin chaperone A25  DNAJB11DnaJ heat shock protein family member B1106  DNAJC10DnaJ heat shock protein family member C1005  PARK7Parkinsonism associated deglycase04**MISMATCH REPAIR**  RFC3replication factor C subunit 350  SSBP1single stranded DNA binding protein 150  MSH6mutS homolog 6(MSH6)55  POLD3DNA polymerase delta 3, accessory subunit23  PCNAproliferating cell nuclear antigen04  POLD1DNA polymerase delta 1, catalytic subunit03**PHAGOSOME/AUTOPHAGY**  DYNC1H1dynein cytoplasmic 1 heavy chain 13829  SEC16ASEC16 homolog A, endoplasmic reticulum export factor1412  TUBB4Atubulin beta 4A class IVa1110  IRS4insulin receptor substrate 41013  TUBB3tubulin beta 3 class III913  TUBB6tubulin beta 6 class V918  PPP2R1Aprotein phosphatase 2 scaffold subunit Aalpha75  CDK5cyclin dependent kinase 570  SEC61BSec61 translocon beta subunit60  HLA-Amajor histocompatibility complex, class I, A55  ANKRD28aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase55  RAB1BRAB1B, member RAS oncogene family50  SLC3A2solute carrier family 3 member 248  SEC24CSEC24 homolog C, COPII coat complex component43  TFRCtransferrin receptor40  AP3M1adaptor related proteincomplex 3 Mu 1 subunit30  PPP6Cprotein phosphatase 6 catalytic subunit30  BAG3BCL2 associated athanogene 323  WDR5WD repeat domain 505  YME1L1YME1 like 1 ATPase04  KEAP1kelch like ECH associated protein 104  DYNC1I2dynein cytoplasmic 1 intermediate chain 204  CDKN2Acyclin dependent kinase inhibitor 2A03  HLA-Bmajor histocompatibility complex, class I, B03**PROTEIN PROCESSING IN THE ENDOPLASMIC RETICULUM**  DNAJA1DnaJ heat shock protein family (Hsp40) member A17076  STUB1STIP1 homology and U-box containing protein 13031  HSPH1heat shock protein family H (Hsp110) member 1198  DNAJA2DnaJ heat shock protein family (Hsp40) member A21516  BAG2BCL2 associated athanogene 21116  SEC61BSec61 translocon beta subunit60  RPN1ribophorin I53  TXNDC5thioredoxin domain containing 552  DNAJB1DnaJ heat shock protein family (Hsp40) member B140  SEC24CSEC24 homolog C, COPII coat complex component43  DDOSTdolichyl-diphosphooligosaccharide\--protein glycosyltransferase 48 kD subunit34  SSR4signal sequence receptor subunit 423  DNAJB11DnaJ heat shock protein family (Hsp40) member B1106  DNAJC10DnaJ heat shock protein family (Hsp40) member C1005  RRBP1ribosome binding protein 103**PROTEOSOME**  PSMC2proteasome 26S subunit, ATPase 22218  PSMD2proteasome 26S subunit, non-ATPase 21810  PSMA7proteasome subunit alpha 71716  PSMD11proteasome 26S subunit, non-ATPase 11149  PSMC3proteasome 26S subunit, ATPase 3129  PSMD3proteasome 26S subunit, non-ATPase 3128  PSMA5proteasome subunit alpha 5116  PSMC5proteasome 26S Subunit, ATPase 51010  PSME3proteasome activator subunit 31011  PSMA6proteasome subunit alpha 690  PSMD6proteasome 26S subunit, non-ATPase 697  PSMA3proteasome subunit alpha 383  PSMD1proteasome 26S subunit, non-ATPase 188  PSMA1proteasome subunit alpha 177  PSMB1proteasome subunit beta 177  PSMB5proteasome subunit beta 566  PSMC1proteasome 26S subunit, ATPase 166  PSMB2proteasome subunit beta 255  PSMB6proteasome subunit beta 655  PSMC4proteasome 26S subunit, ATPase 450  PSMC6proteasome 26S subunit, ATPase 656  PSMD12proteasome 26S subunit, non-ATPase 1242  PSMD7proteasome 26S subunit, non-ATPase 730  PSMD13proteasome 26S subunit, non-ATPase 1303  PSMD14proteasome 26S subunit, non-ATPase 1403  PSMD8proteasome 26S subunit, non-ATPase 806**RNA TRANSPORT**  RANBP2RAN binding protein 22925  XPO1exportin 11313  NUP93nucleoporin 931110  NUP133nucleoporin 1331015  THOC2THO complex 296  RANGAP1Ran GTPase activating protein 1811  KPNB1karyopherin subunit beta 175  KPNA2karyopherin subunit alpha 264  EIF4A1eukaryotic translation initiation factor 4A154  EIF4G1eukaryotic translation initiation factor 4 gamma 154  NUP155nucleoporin 15546  NUP210nucleoporin 21040  EIF3Feukaryotic translation initiation factor 3 subunit F33  FXR2FMR1 autosomal homolog 230  NUP160nucleoporin 16034  NUP205nucleoporin 20534  EIF3Eeukaryotic translation initiation factor 3 subunit E24  FMR1fragile X mental retardation 120  NUP98nucleoporin 9825  NUP153nucleoporin 15305  THOC3THO complex 304  XPOTexportin for tRNA04**UBIQUITINATION / SUMOYLATION**  STUB1STIP1 homology and U-box containing protein 13031  HUWE1HECT, UBA and WWE domain containing 1, E3 ubiquitin ligase2920  RANBP2RAN binding protein 2, E3 SUMO ligase2925  RNF40ring finger protein 40, E3 ubiquitin ligase410  USP7ubiquitin specific peptidase 749  USP9Xubiquitin specific peptidase 9, X-linked45  RNF2ring finger protein 2, , E3 ubiquitin protein ligase30  UBR5ubiquitin protein ligase E3 component n-recognin 5312  USP15ubiquitin specific peptidase 1530  SUMO3small ubiquitin-like modifier 303  MKRN2makorin ring finger protein 2, E3 ubiquitin ligase03

To further confirm the effectiveness of our MS analyses, we next analyzed some of the interactors identified. To do that, a subset of cDNAs identified from the SMCR8 proteome were cloned with an N-terminal V5-TEV (tobacco etch virus)-epitope tag or were obtained as gifts. Notably, following cotransfection in 293T cells, 73% (22/30) of proteins tested directly co-IPed with FL-SMCR8 on α-FLAG agarose, further confirming the efficiency of our protocol (Fig. [2](#Fig2){ref-type="fig"}). In almost all cases, interactions were resistant to RNase digestion. Some proteins bound non-specifically to the agarose (BAG5, PPP2R1A, RUVBL2) or failed to bind FL-SMCR8 (G3BP1, GTF2I, RAB1A, RANGAP1, STIP1). It is possible some of these latter proteins are only able to bind SMCR8 when in complex with over-expressed C9orf72 and/or WDR41. Fig. 2Confirmation of proteins in the SMCR8 complex. Selected proteins detected in the SMCR8 interactome by MS sequencing were tagged and coexpressed with SMCR8 in HEK 293T cells. Most were found to specifically co-IP on α-FLAG agarose with FL-SMCR8 but not empty vector. Approximately 1% of the input lysate (lanes 1, 2) and 30% of the immunoprecipitate (lanes 4--7) were loaded on gels. IP reactions were in the presence or absence of 50 μg/ml RNases. Also included is a panel representative of tagged FL-SMCR8 protein present in the input and IP fractions (detected by α-FLAG antibody) and showing that RNase treatment did not affect SMCR8 immunoprecipitation (lower right). Test proteins were detected by α-V5 antibody, except FL-UBR5, which was detected by α-FLAG antibody (bottom right). The molecular weight of each test protein, including its epitope tag, is shown in brackets. Protein molecular weight markers are those of Novex Sharp Pre-stained Protein Standard (Thermo Fisher)

Several studies have proposed a role for C9orf72 in the regulation of autophagy by Rab GTPases, although with disagreement concerning which of the many Rab family members binds the C9orf72/SMCR8/WDR41 complex. Farg et al. \[[@CR43]\] first reported C9orf72 to interact with RAB1, RAB5, RAB7 and RAB11. Webster et al. \[[@CR22]\] confirmed that C9orf72 associates with GTP-bound RAB1A and the ULK1 complex, and it has been demonstrated that C9orf72 in complex with SMCR8 and WDR41 is a GEF for RAB8A, RAB11A, and RAB39B, and that its loss perturbs autophagy in neurons \[[@CR27], [@CR29], [@CR31], [@CR89]\]. We detected only RAB1B in our SMCR8 and C9orf72 interactomes (Tables [S1](#MOESM1){ref-type="media"}, [S2](#MOESM1){ref-type="media"}), but failed to confirm binding of V5-tagged RAB1A, a paralog highly similar in sequence to RAB1A, with SMCR8 in direct co-IP experiments. However, we also tested and confirmed weak binding of V5-RAB7A with overexpressed SMCR8 (Fig. [2](#Fig2){ref-type="fig"}) and C9orf72 (not shown), but only in the presence of RNase.

Significantly, when we queried the OMIM (Online Mendelian Inheritence in Man) database (<https://omim.org/>), we found that 65 (19%) of our putative SMCR8-interacting proteins are associated with neurodegenerative and neurological genetic disorders (Table [2](#Tab2){ref-type="table"}). These include 8 proteins linked with ALS and/or FTD, 14 with other neurodegenerative diseases (including 4 associated with spinocerebellar ataxias), 7 with Charcot-Marie Tooth disease, 5 with hypomyelinating leukodystrophy, and 13 with mental retardation. Thus, SMCR8 may recruit some of these proteins to its complex with C9orf72 and WDR41, predicting roles for the complex in central nervous system (CNS) disorders. Table 2Proteins of the SMCR8 interactome associated with CNS disease according to the Online Mendelian Inheritance in Man (OMIM) databaseGENE NAMEDISEASE NAMESYMBOLOMIM \#**ALS/FTD** ATXN2Amyotrophic lateral sclerosis 13ALS13183,090 C9orf72Frontotemporal dementia and/or amyotrophic lateral sclerosis 1FTDALS1105,550 DCTN1Amyotrophic lateral sclerosisALS105,400 FIG4Amyotrophic lateral sclerosis 11ALS11612,577 FUSAmyotrophic lateral sclerosis 6, with or without frontotemporal dementiaALS6608,030 MATR3Amyotrophic lateral sclerosis 21ALS21606,070 SQSTM1Frontotemporal dementia and/or amyotrophic lateral sclerosis 3FTDALS3616,437 TARDBPAmyotrophic lateral sclerosis 10ALS10612,069**OTHER NEURODEGENERATION DISEASES** AIFM1Combined oxidative phosphorylation deficiency 6COXPD6300,816 ATXN2Spinocerebellar ataxia 2SCA2183,090 CTSDCeroid lipofuscinosis, neuronal, 10CLN10610,127 DYNC1H1Spinal muscular atrophy, lower extremity-predominant 1, autosomal dominantSMALED1158,600 EIF4G1Parkinson disease 18PARK18614,251 NOP56Spinocerebellar ataxia 36SCA36614,153 PARK7Parkinson disease 7PARK7606,324 PCNAAtaxia-telangiectasia-like disorder 2ATLD2615,919 PUM1Spinocerebellar ataxia 47SCA47617,931 QARSMicrocephaly, progressive, with seizures and cerebral and cerebellar atrophyMSCCA615,760 RARSLeukodystrophy, hypomyelinating, 9HLD9616,140 SPG20Spastic paraplegia 20, autosomal recessiveSPG20275,900 STUB1Spinocerebellar ataxia, autosomal recessive, 16SCAR16615,768 WNK1Neuropathy, hereditary sensory and autonomic, 2AHSAN2A201,300**OTHER NEUROLOGICAL CONDITIONS** ADARAicardi-Goutieres syndrome 6AGS6615,010 ADNPHelsmoortel-van der Aa syndromeHVDAS615,873 AIFM1Cowchock syndromeCOWCK310,490 AIMP1Leukodystrophy, hypomyelinating, 3HLD3260,600 AIMP2Leukodystrophy, hypomyelinating, 17HLD17618,006 ALDH18A1Spastic paraplegia 9A, autosomal dominantSPG9A601,162 ALDH18A1Spastic paraplegia 9B, autosomal recessiveSPG9B616,586 ALDH3A2Sjogren-Larsson syndromeSLS270,200 ARHGEF2Neurodevelopmental disorder with midbrain and hindbrain malformationsNEDMHM617,523 ATAD3AHarel-Yoon syndromeATAD3A612,316 ATP1A1Charcot-Marie-Tooth disease, axonal, type 2DDCMT2DD618,036 CADEpileptic encephalopathy, early infantile, 50AR616,457 CDK5Lissencephaly 7, with cerebellar hypoplasiaLIS7616,342 CLTCMental retardation, autosomal dominant 56MRD56617,854 COPB2Microcephaly 19, primary, autosomal recessiveMCPH19617,800 DARSHypomyelination with brainstem and spinal cord involvement and leg spasticityHBSL615,281 DCTN1Neuronopathy, distal hereditary motor, 7BHMN7B607,641 DCTN1Perry syndromePERRYS168,605 DOCK7Epileptic encephalopathy, early infantile, 23AR615,859 DYNC1H1Charcot-Marie-Tooth disease 2OCMT2O614,228 DYNC1H1Mental retardation, autosomal dominant 13MRD13614,563 EPRSLeukodystrophy, hypomyelinating, 15HLD15617,951 FIG4Polymicrogyria, bilateral temporooccipitalBTOP612,691 FIG4Charcot-Marie-Tooth disease 4 JCMT4J611,228 FKBP5{Major depressive disorder and accelerated response to antidepressant drugs}MDD608,516 FMR1Fragile X syndromeFRAX300,624 FMR1Fragile X tremor/ataxia syndromeFXTAS300,623 GATAD2BMental retardation, autosomal dominant 18MRD18615,074 HCFC1Mental retardation, X-linked 3MRX3309,541 HNRNPH2Mental retardation, X-linked, syndromic, Bain typeMRXSB300,986 HPRT1Lesch-Nyhan syndromeLNS300,322 HSD17B4Perrault syndrome 1PRLTS1233,400 HSPB1Neuropathy, distal hereditary motor, type IIBHMN2B608,634 HSPB1Charcot-Marie-Tooth disease 2FCMT2F606,595 HUWE1Mental retardation, X-linked 17MRX17300,705 HUWE1Mental retardation, X-linked, syndromic, Turner typeMRXST300,706 LAS1LWilson-Turner syndromeWTS309,585 LMNACharcot-Marie-Tooth disease 2B1CMT2B1605,588 LRPPRCLeigh syndrome French-Canadian typeLSFC220,111 MARSCharcot-Marie-Tooth disease 2 UCMT2U616,280 MTHFD1Neural tube defects, folate-sensitiveNTDFS601,634 NSUN2Mental retardation, autosomal recessive 5MRT5611,091 PDK3Charcot-Marie-Tooth disease, X-linked dominant, 6CMTX6300,905 PPP2R1AMental retardation, autosomal dominant 36MRD36616,362 PSMD12Stankiewicz-Isidor syndromeSTISS617,516 RANBP2Encephalopathy, acute, infection-induced, 3IIAE3608,033 SAMHD1Aicardi-Goutieres syndrome 5AGS5612,952 SLC25A1Combined D-2- and L-2-hydroxyglutaric aciduriaD2L2AD615,182 SLC25A22Epileptic encephalopathy, early infantile, 3EIEE3609,304 SPTLC1Neuropathy, hereditary sensory and autonomic, type IAHSN1A162,400 TECRMental retardation, autosomal recessive 14MRT14614,020 THOC2Mental retardation, X-linked 12MRX12300,957 TUBB3Cortical dysplasia, complex, with other brain malformations 1CDCBM1614,039 TUBB4ALeukodystrophy, hypomyelinating, 6HLD612,438 USP9XMental retardation, X-linked 99MRX99300,919 USP9XMental retardation, X-linked 99, syndromic, female-restrictedMRXS99F300,968

SMCR8 associates with proteins of the ubiquitination and protein decay pathways {#Sec11}
-------------------------------------------------------------------------------

Our MS analyses also showed that both SMCR8 and C9orf72 proteins bind the proteasome. Our lists of SMCR8- and C9orf72-interactors were examined for KEGG pathways using the DAVID Functional Annotation Tool (NIAID, NIH, \[[@CR83]\]). In the case of SMCR8-associated proteins, proteasome (7.6% of total proteins), RNA transport (6.2%), and protein processing in the endoplasmic reticulum (4.4%) pathways predominated (Fig. [S2](#MOESM1){ref-type="media"}A). For C9orf72, proteins associated with the proteasome and RNA transport pathways accounted for 4.5 and 8% of the total, respectively, while spliceosome pathway proteins (9%) were most abundant (Fig. [S2](#MOESM1){ref-type="media"}B). Twenty-six proteasome subunits co-IPed with FL-SMCR8, and 9 subunits were detected within the C9orf72-FL interactome. Furthermore, based on KEGG and Autophagy Database (<http://www.tanpaku.org/autophagy/>) analyses, 24 proteins involved with phagosome and autophagy pathways were detected in the SMCR8 interactome, including proteins linked with neurological diseases (CDK5, DYNC1H1, HUWE1, PPP2R1A, RANBP2, STUB1, TUBB3, TUBB4A, and USP9X; Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [S2](#MOESM1){ref-type="media"}).

Our SMCR8 interactome also contained 9 ubiquitination pathway factors, including ubiquitin ligases and peptidases (Table [1](#Tab1){ref-type="table"}). Therefore, we examined MS-sequenced peptides deriving from immunoprecipitated FL-SMCR8 for ubiquitin modification (72% coverage of the total protein). A total of 9 high confidence modified lysine residues were predicted by at least 5 peptides in two independent experiments, suggesting that SMCR8 is highly ubiquitinated. Eight of these lysines were also identified by at least one of three ubiquitination prediction algorithms, including UbPred \[[@CR86]\], BDM-PUB (<http://bdmpub.biocuckoo.org>), and UbiSite (<http://csb.cse.yzu.edu.tw/UbiSite/>) (Table [S3](#MOESM1){ref-type="media"}). We then considered the phylogenic conservation of these lysines by aligning SMCR8 protein sequences from 8 vertebrate (human, chimpanzee, dog, mouse, rat, chicken, zebrafish, and frog) and two mollusc (freshwater snail and sea slug) species (Fig. [S3](#MOESM1){ref-type="media"}). Eight of the 9 lysines detected by MS as modified were conserved among at least 8 species, including 2 residues (K232, K479) found in both molluscs, suggesting that these post-translational modifications (PTMs) might be functionally relevant.

Immunoprecipitating FLAG-tagged SMCR8 and probing with α-ubiquitin on Western blots reveals high-molecular weight (HMW) proteins consistent with polyubiquitinated SMCR8 and/or other large ubiquitinated proteins bound in the SMCR8 complex (Fig. [3](#Fig3){ref-type="fig"}a). In whole cell lysates, SMCR8-V5, in the presence of the proteasome inhibitor MG-132 and/or coexpressed ubiquitin, showed HMW products consistent with multiple PTMs (Fig. [3](#Fig3){ref-type="fig"}b). Furthermore, FLAG-tagged ubiquitin coimmunoprecipitates on α-FLAG agarose, and so by implication is conjugated to cotransfected HA- or V5-tagged SMCR8 (Fig. [3](#Fig3){ref-type="fig"}c). Although treatment with MG132 caused accumulation of HMW SCMR8 protein species, suggesting their regulation by the ubiquitin-proteasome system (UPS), full-length SMCR8 signal was little decreased in the presence of coexpressed ubiquitin (Fig. [3](#Fig3){ref-type="fig"}b,c). Fig. 3Evidence that SMCR8 protein is poly-ubiquitinated. **a** The FL-SMCR8 construct was transfected in 293T cells and immunoprecipitated with α-FLAG antibody-bound agarose. A Western blot of whole cell lysates probed with α-FLAG antibody shows expression of full-length FL-SMCR8 protein plus HMW products consistent with PTMs (left). Probing with α-UBB antibody marks HMW products in immunoprecipitates consistent with either poly-ubiquitinated FL-SMCR8 protein or the presence of other HMW ubiquitinated proteins that co-IP with the SMCR8 complex (right). IP reactions were in the presence or absence of 50 μg/ml RNases. **b** C-terminal V5-tagged SMCR8 and empty vector or HA-tagged ubiquitin were coexpressed in 293T cells and treated or not treated with the proteasome inhibitor MG132. Expression of SMCR8-V5 protein and empty vector, in the presence but not absence of MG132, produces HMW bands on Western blots that are consistent with post-translational modification of SMCR8 at multiple sites. SMCR8-V5 protein coexpressed with HA-UBB and without MG132 shows the same HMW bands, which increase in signal intensity upon incubation with MG132. **c** V5- or HA-epitope-tagged SMCR8 was coexpressed with empty vector or FLAG-tagged UBB in 293T cells and incubated overnight in the presence or absence of MG132. Cell lysates were subjected to immunoprecipitation with α-FLAG agarose, followed by Western blotting and probing with α-HA (top left panel), α-V5 (top right) or α-FLAG (bottom left) antibodies. A HMW smear seen in immunoprecipitates is consistent with poly-ubiquitination of tagged SMCR8 proteins. In general, overexpression of ubiquitin does not lead to a significant decrease in full-length SMCR8 protein levels

Using confocal IF microsopy, we observed that overexpression of red fluorescent protein (RFP)-tagged ubiquitin induces formation of a large aggregate consistent with the aggresome and marked by colocalization with coexpressed and therefore likely UBB-bound FL-SMCR8 (Fig. [4](#Fig4){ref-type="fig"}a). Aggresomes appear mainly within an indentation of the nucleus at the microtubule-organizing center and form when the protein-degradation machinery of the cell is overwhelmed \[[@CR90]\]. Misfolded and ubiquitinated proteins, including perhaps SMCR8, are transported to the aggresome along the microtubule network by means of the dynein motor complex (which includes cytoplasmic dyneins DYNC1H1 and DYNC1I2, both detected in FL-SMCR8 iimmunoprecipitates, Table [S2](#MOESM1){ref-type="media"}). An alternative ubiquitin-independent pathway involves interaction of STUB1 and BAG3, which transfer misfolded proteins to heat shock protein 70 (all proteins that co-IPed with FL-SMCR8, Table [S2](#MOESM1){ref-type="media"}) and the dynein motor complex to promote formation of aggresomes \[[@CR91], [@CR92]\]. Fig. 4Immunofluorescence microscopy shows evidence for association of endogenous SMCR8 protein with cytoplasmic aggregates. **a** FLAG-tagged SMCR8 and RFP-tagged ubiquitin transfected in 2102Ep cells colocalize in a structure consistent with the aggresome. **b** Overexpression of V5-tagged C9orf72 does not induce stress granule formation in unstressed U2OS cells. **c** Exogenously expressed HA-SMCR8 protein is not observed in SGs of U2OS cells stressed with NaAsO~2~. **d** WDR41-FL protein does not colocalize with SG marker protein TIA1 in U2OS cells stressed with NaAsO~2~. **e** Endogenous C9orf72 protein detercted by the α-SMCR8-SC antibody does not colocalize with SGs in NaAsO~2~-stressed U2OS cells (see also Fig. [S4](#MOESM1){ref-type="media"}E). **f** Endogenous C9orf72 protein detected by the C9-L antibody \[[@CR54]\] does not colocalize with SGs in DTT-stressed U2OS cells. **g**,**h** Endogenous SMCR8 detected by the α-SMCR8-ab202283 antibody localizes to SGs of stressed (**h**), but not unstressed (**g**) U2OS cells (see also Fig. [S4](#MOESM1){ref-type="media"}G-I). **i** The α-WDR41-SC antibody does not detect endogenous protein in SGs of NaAsO~2~-stressed 2102Ep cells. NT: no treatment. Cell nuclei were stained with Hoechst 33342 (right-most panels). Size bars are 10 μm

Thus, SMCR8 protein is bound by ubiquitin and may recruit UPS complexes to the vicinity of its other associated cellular proteins, numbers of which have been linked with neuropathologies (Table [2](#Tab2){ref-type="table"}).

Evidence that endogenous SMCR8 accumulates in cytoplasmic stress granules {#Sec12}
-------------------------------------------------------------------------

The accumulation of neuronal RNA and protein aggregates, including cytoplasmic stress granules, is a pathogenic hallmark of a number of neurodegenerative diseases, among them FTD and ALS \[[@CR93]--[@CR95]\]. SGs assemble rapidly under cellular stress and include the small, but not large, ribosomal subunits bound to translation initiation factors such as eIF2 and eIF3 (reviewed in \[[@CR96]\]). Processing-bodies (PBs) and SGs are dynamic cytoplasmic aggregates that participate in mRNA decay, and SGs in mammalian cells are heavily ubiquitinated \[[@CR97]\]. Because previous publications implicated C9orf72 protein expression in the metabolism of SGs \[[@CR88], [@CR98]\], we wished to determine if the C9orf72 binding partner SMCR8 associates with SGs in various tumor cell lines.

As reported by others \[[@CR28]\], we observed epitope-tagged SMCR8 and C9orf72 proteins to both have a diffuse cytoplasmic distribution with protein also observed in nuclei, although nuclear localization was more evident for C9orf72 (Fig. [4](#Fig4){ref-type="fig"}b,c, S4A-C). However, although Maharjan et al. \[[@CR98]\] reported that SGs were induced in a majority of unstressed mouse Neuro2A (N2A) neuroblastoma cells when transfected with myc-tagged C9-L, we failed to observe this phenomenon for tagged C9-L or SMCR8 proteins transfected alone or in combination (not shown) in unstressed human osterosarcoma U2OS, HEK 293T, or neuroblastoma cell lines (Fig. [4](#Fig4){ref-type="fig"}b, S4B). Furthermore, when cells were treated with 250 μM of the oxidative stressor sodium arsenite (NaAsO~2~) for 80 min, tagged C9orf72, SMCR8, or WDR41 protein very rarely colocalized in aggregates with endogenous canonical SG marker protein TIA1 in multiple cell lines (Figs. [4](#Fig4){ref-type="fig"}c,d, S4C).

We next examined localization of endogenous C9orf72 and SMCR8 proteins in cells. The α-C9orf72-SC and α-C9orf72-PT antibodies both detected nuclear and cytoplasmic distribution for C9orf72 protein, with fine cytoplasmic granululazion visible in unstressed cells that was more evident for the latter antibody (Fig. [S4](#MOESM1){ref-type="media"}D). However, contrary to previous studies that used these antibodies to report SG localization \[[@CR88], [@CR98]\], we failed to detect endogenous C9orf72 in stress-induced U2OS (Figs. [4](#Fig4){ref-type="fig"}e, S4E) or 2102Ep (not shown) cells, although C9orf72 infrequently justaposed or overlapped with SGs and/or PBs in N2A cells (Fig. [S4](#MOESM1){ref-type="media"}F.G). To confirm further these observations, two polyclonal antibodies developed by the Robertson lab \[[@CR19], [@CR79]\], and specific for C9-L (Fig. [4](#Fig4){ref-type="fig"}f) and C9-S (not shown) isoforms, were also tested but failed to show obvious C9orf72 protein presence in TIA1-marked SGs in DTT- or NaAsO~2~-stressed cells of multiple lines, including U2OS and 2012Ep cells. Thus, detection of C9orf72 in SGs appears to be cell line and possibly antibody dependent.

We also used the α-SMCR8-PT and α-SMCR8-ab202283 antibodies to examine endogenous SMCR8 protein localization. In unstressed U2OS cells, endogenous SMCR8 was nuclear and more prominently cytoplasmic with speckled staining (Fig. [4](#Fig4){ref-type="fig"}g). However, when cells were stressed with NaAsO~2~, SMCR8 redistributed to large intensely staining foci that colocalized with TIA1 (Fig. [4](#Fig4){ref-type="fig"}h). Fig. [S4](#MOESM1){ref-type="media"}H shows SMCR8 protein in large cytoplasmic aggregates of NaAsO~2~-stressed HEK 293T cells that costain with a different endogenous SG marker, the LINE-1 retrotransposon-encoded ORF1 protein \[[@CR81]\], while Fig. [S4](#MOESM1){ref-type="media"}I shows costaining with SG-marker eIF3η in human neuroblastoma SK-N-SH cells. In N2A cells treated with the endoplasmic reticulum stressor thapsigargin, SMCR8 granules were marked by a p70 S6 kinase antibody known to recognize HEDLS/EDC4, a PB component (Fig. [S4](#MOESM1){ref-type="media"}J, \[[@CR77]\]): PBs frequently overlap or juxtapose with SGs in stressed cells \[[@CR99]\]. Endogenous SMCR8 granules in unstressed N2A cells also partially colocalized with GW182 autoantigen, which marks PBs (Fig. [S4](#MOESM1){ref-type="media"}K) \[[@CR80]\]. However, as noted above, SMCR8 commercial antibodies detect multiple protein species (Fig. [S1](#MOESM1){ref-type="media"}B-E), some possibly non-specific, and we cannot be certain that canonical full-length endogenous SMCR8 proteins are what we see in SGs. Nevertheless, our data suggest that in stressed cells a fraction of endogenous SMCR8 protein is directed to cytoplasmic SGs.

Our analyses showed that TAR DNA binding protein 43 (TDP-43, product of the TARDBP gene) binds SMCR8 (Fig. [2](#Fig2){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). Mutations in TARDBP are involved in about 4% of familial and 1% of sporadic ALS (sALS) cases. However, even wild-type TDP-43, while mostly nuclear in healthy cells, is cleaved and hyperphosphorylated and accumulates in ubiquitinated cytoplasmic aggregates in neurons of almost all ALS and about half of FTLD patients (reviewed in \[[@CR100]\]). We tested if endogenous or overexpressed SMCR8 protein colocalizes with TDP-43 protein in cytoplasmic granules but found this not to be the case in unstressed or stressed U2OS or 2102Ep cells (Fig. [S4](#MOESM1){ref-type="media"}L).

Hexanucleotide expansions within transcripts of the C9orf72 ALS gene may undergo non-conventional repeat-associated non-ATG (RAN) translation and generate dipeptide repeats that aggregate in the cytoplasm of neuronal cells of C9ALS patients (reviewed in \[[@CR101]\]). To see if such aggregates might colocalize with SMCR8, we coexpressed in 293T cells FL-SMCR8 and a C9orf72 RAN translation product of 50 GA-dipeptide repeats tagged with EGFP \[[@CR68]\]. Overexpressed dipeptide proteins formed one to three large cytoplasmic aggrgates in each cell that were were ringed by, but mostly excluded SMCR8 (Fig. [S4](#MOESM1){ref-type="media"}M).

Finally, the α-WDR41-SC antibody marks WDR41 protein as predominantly nuclear but also with faint cytoplasmic granules that fail to colocalize with SGs in unstressed or stressed U2OS, 2102Ep, 293T, or N2A cells (Fig. [4](#Fig4){ref-type="fig"}i and not shown). On the other hand, the α-WDR41-PT antibody colocalizes with a minor subset of granules positive for 4-ET, a marker of PBs (Fig. [S4](#MOESM1){ref-type="media"}N). However, while the α-WDR41-SC antibody recognizes only bands consistent in size with WDR41 isoforms in HEK 293T, 2102Ep, and SK-N-SH cells (Fig. [S1](#MOESM1){ref-type="media"}F), the α-WDR41-PT antibody detects other non-canonical protein species (Fig. [S1](#MOESM1){ref-type="media"}G), and the specificity of its SG staining is thus uncertain.

Searching the Mammalian Stress Granules Proteome Database (<https://msgp.pt>) \[[@CR102]\], we found that 18% of the SMCR8 proiein interactome (61/340) and 26% (35/201) of the C9orf72 interactome are known SG-associated proteins. It is thus possible that SG components bind endogenous SMCR8-C9orf72 complexes and shepherd them to SGs, although why this would not also be the case for overexpressed exogenous SMCR8 or C9orf72 proteins is unclear.

SMCR8 expression in ALS patient brain tissues {#Sec13}
---------------------------------------------

Despite its strong association with protein-degradation factors, SMCR8 overexpression does not stimulate degradation of C9orf72 protein with which it is in complex. Contrarily, multiple studies in cells and knockout mice have shown that protein but not RNA levels of *SMCR8* and *C9orf72* are positively correlated, suggesting that in complex the two proteins stabilize and protect each other from degradation \[[@CR26], [@CR28], [@CR29], [@CR32], [@CR47], [@CR54], [@CR65], [@CR103]\]. On the other hand, increased SMCR8 protein reportedly has little effect on WDR41 levels in KO mice or cells \[[@CR32], [@CR35]\]. We confirmed in 293T cells that overexpression of SMCR8 with various tags strongly increased levels of cotransfected FL-C9-L protein, while cotransfection of empty vectors or an unrelated protein (RO60) did not (Fig. [5](#Fig5){ref-type="fig"}a). Considering the interplay between SMCR8 and C9orf72 proteins, and the fact that *C9orf72* RNA expression is reduced in some C9ALS patient cohorts, we asked if SMCR8 expression levels are altered in the brains of C9ALS patients compared with non-affected controls. Fig. 5Expression of C9orf72 and SMCR8 proteins are positively correlated in cell lines and human brain tissues. **a** C9orf72-FL was coexpressed in HEK 293T cells with 3 different epitope-tagged SMCR8 constructs, FLAG-tagged RO60 protein, or empty vectors (pcDNA3 and pcDNA6 myc/his B). A Western blot of whole cell lysates was probed sequentially with rb α-FLAG, ms α-HA, ms α-V5, and rb α-HSP90 antibodies, the latter as a loading control. At the exposure time for the film shown, expression of C9orf72-FL was not seen in the presence of empty vector or RO60-FL, but signal was robust in the presence of SMCR8. **b** Western blot of brain motor cortex tissue lysates of C9ALS patients (lanes 1--5) and unaffected control individuals (lanes 6--9) probed with α-SMCR8 and α-HSP90 antibodies. Sample names are shown above the panels (see Table [S4](#MOESM1){ref-type="media"}). Numbers below the middle panel are normalized ratios of SMCR8 to HSP90 expression determined by ImageJ analysis of band intensities and calculated as described in the text. The lower panel shows the approximately 150-kD unspecified band detected by α-WDR41-SC antibody in human brain tissue lysates (see Fig. [S1](#MOESM1){ref-type="media"}F): this panel is included only as an additional loading control and is not intended to show expression of canonical WDR41 protein. Approximtely 50 μg of protein was loaded in each lane. **c** Dot plot of ratios of SMCR8 to HSP90 protein band intensities determined by ImageJ analyses of brain tissues lysates from 11 C9ALS and 10 control individuals. Each sample point is the average of 2 to 4 independent Western blot analyses. A short horizontal line indicates mean values. The presence of a C9orf72 hexanucleotide expansion in each C9ALS carrier individual was confirmed by Columbia University and Target ALS using RP-PCR and Illumina Expansion Hunter, but expansion copy numbers are not known

We first examined transcription levels of *C9orf72*, *SMCR8*, and *WDR41* genes in RNA-Seq datasets from several sequence read archives that contain C9ALS sample data. GEO dataset GSE67196 includes cerebellum and frontal cortex samples of 9 healthy, 8 C9ALS, and 10 sALS individuals. Using TEtranscripts \[[@CR84]\] to analyze *C9orf72* gene expression levels, we found a significant log~2~ 0.96-fold decrease (padj 4.6E-5) in the frontal cortex of C9ALS vs sALS individuals and a 1.1-fold decrease (padj 1.6-E4) in the cerebellum of C9ALS vs control individuals; however, in neither case was decrease in *SMCR8* expression significant. The NeuroLINCS dbGaP Study phs001231 (SRP098831) consists of poly(A) + non-stranded mRNA of iPSC-derived motor neurons from 4 C9ALS, 3 spinal muscular atrophy (SMA), and 3 unaffected individuals (2 or 3 replicates each). No significant changes in *C9orf72* or *SMCR8* transcript levels were seen in this dataset, although *WDR41* sequence read numbers were reduced about 0.35-fold in both C9ALS vs control and SMA vs control samples (padj\< 0.01). Finally, a recent RNA-Seq study comparing C9 FTLD and FTLD/motor neuron disease patients with unaffected control individuals reported a highly significant decrease in *C9orf72* RNA levels in C9 FTLD samples; however, this data showed no significant change in *SMCR8* or *WDR41* RNA expression \[[@CR24]\].

We next assayed endogenous SMCR8 protein expression levels in the context of the *C9orf72* hexanucleotide expansion. Motor cortex brain tissue lysate samples of 11 C9ALS and 10 unaffected control individuals were analyzed by Western blotting with α-SMCR8 antibodies (Fig. [5](#Fig5){ref-type="fig"}b, Table [S4](#MOESM1){ref-type="media"}). Multiple film exposures were made to optimize signal to noise. Individual band intensities were quantitated with ImageJ software \[[@CR104]\] and normalized against the summed exposures of all equivalent bands on the same gel. SMCR8 signal was then normalized to endogenous HSP90 protein signal detected on the same gel after reprobing with α-HSP90 antibody. Remarkably, an average 5-fold reduction in SMCR8 protein signal was seen in C9ALS vs control tissues (Fig. [5](#Fig5){ref-type="fig"}b). We also tested by Western blotting cerebrospinal fluid samples from 5 C9ALS patients and 5 unaffected controls, but were unable to detect full-length SMCR8 protein signal with either the α-SMCR8-PT or α-SMCR8-ab202283 antibodies (not shown). We also plotted normalized SMCR8 protein signal against ALS disease duration in months (Table [S4](#MOESM1){ref-type="media"}), finding a weak negative but non-significant correlation (*r* = 0.34). Nevertheless, altogether our data recommend further investigation of SMCR8 protein level as a potential biomarker of the *C9orf72* expansion disease mutation.

Discussion {#Sec14}
==========

In this study we characterized the SMCR8 protein interactome and found it to include numerous components of the ubiquitin-proteasome system, including ubiquitin ligases and peptidases. Of note, the IP method used here exploited FLAG-tagged proteins and so overcame limitations imposed by differences in isoform expression and non-specific protein species recognized by C9orf72 and SMCR8 antibodies. Despite evidence that SMCR8 itself is ubiquitinated at multiple residues, its degradation is not significantly induced in the presence of overexpressed ubiquitin suggesting other roles linking it with the UPS. Recruitment of UPS components to autophagy complexes could be one such role, and our SMCR8 interactome contains 24 autophagy pathway-associated proteins (Table [1](#Tab1){ref-type="table"}). Ubiquitin plays a fundamental role not only in proteasome-mediated protein degradation but also in the targeting of proteins for degradation by autophagic complexes. Protein ubiquitination also regulates multiple steps of the autophagy pathway (reviewed in \[[@CR105], [@CR106]\]). For example, E3 ubiquitin ligase STUB1, a protein that co-IPs with SMCR8 (Table [1](#Tab1){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}), regulates autophagy by targeting TFEB for degradation by the UPS \[[@CR107]\]. Also, E3 ligase HUWE1 (Table [1](#Tab1){ref-type="table"}) mediates the ubiquitination and proteasomal degradation of WIPI2, a protein involved in autophagosome formation \[[@CR108]\].

Recruitment of ubiquitination factors would be consistent with reported roles of the C9orf72-SMCR8 complex in autophagy and endosomal-lysosomal metabolism. The C9orf72/SMCR8/WDR41 complex associates with the ATG8 autophagy receptor network and influences activity of the ULK1-RB1CC1-ATG13-ATG101 autophagy initiation complex (RB1CC1 was detected in both our SMCR8 and C9orf72 protein interactomes, Tables [S1](#MOESM1){ref-type="media"}, [S2](#MOESM1){ref-type="media"}) \[[@CR22], [@CR28], [@CR29], [@CR31], [@CR34]\]. C9orf72 and SMCR8 reportedly also play roles in regulating mTORC1 and TFEB autophagy and lysosomal gene transcription factors upstream of autophagy \[[@CR26], [@CR31], [@CR32], [@CR34], [@CR57], [@CR103], [@CR109], [@CR110]\]. Ugolino et al. \[[@CR32]\], however, indicated a negative effect of C9orf72 on autophagy, and Yang et al. \[[@CR31]\] reported increased autophagic flux in C9orf72 knockdown MEF cells, opposite to the reduction they saw in SMCR8-deficient cells. Unlike some *C9orf72*-deficient mice \[[@CR45]\], *Smcr8* KO mice showed motor behavior defects, including axonal swelling due to impaired autophagy and motor neuron axonal transport of autophagosomes \[[@CR25]\]. Apparently, although in complex, some biological roles of C9orf72 and SMCR8 proteins differ.

Association of the SMCR8-C9orf72 complex with the UPS and autophagy would also be consistent with stress granule localization, since protein ubiquitination regulates SG dynamics. Components of the UPS, including ubiquitin, co-localize with SGs, while proteasome inhibition, and consequent increase in ubiquitinated proteins, induces SG formation \[[@CR111]--[@CR113]\]. Recent evidence also suggests SGs are regulated by autophagy \[[@CR114], [@CR115]\], and it has been proposed that improper metabolism of SGs could be involved in ALS pathology \[[@CR93], [@CR94]\]. Interestingly, Chitiproulu et al. \[[@CR88]\] proposed that C9orf72 protein associates with autophagy cargo receptor p62 (encoded by the *SQSTM1* gene) to control SG elimination rather than assembly by forming a complex that eliminates by autophagy SG proteins dimethylated on arginines (of note, we found p62 in the SMCR8 but not C9orf72 interactomes; Fig. [2](#Fig2){ref-type="fig"}, Table [2S](#MOESM1){ref-type="media"}).

However, our data disagree in some aspects with previously published results concerning C9orf72 colocalization with SGs. While, Maharjan et al. \[[@CR98]\] reported that overexpression of myc-tagged C9-L led to the spontaneous appearance of SGs in a majority of N2A cells and cortical neurons in the absence of cellular stress, we failed to reproduce these observations in either U2OS or N2A cells for tagged C9orf72 or SMCR8 proteins, overexpressed together or separately. Furthermore, using the α-C9orf72-PT antibody (Fig. [S1](#MOESM1){ref-type="media"}A), Maharjan et al. \[[@CR98]\] noted that endogenous C9orf72 protein colocalized with a fraction of SGs in neuronal cell lines and cortical neurons in response to DTT and heat shock-induced cell stress, and that C9orf72 depletion inhibited SG assembly, impaired expression of proteins required for their formation, and increased cell sensitivity to stress. However, despite testing several antibodies, cell lines and conditions, we could not detect endogenous C9orf72 in SGs of selected non-neuronal cancer-derived cell lines, and we saw only minor colocalization of C9orf72 with SGs and PBs of N2A cells. Thus, association of C9orf72 protein to SGs appears to be cell line-dependent.

On the other hand, we observed endogenous, but not exogenously expressed, SMCR8 protein localization to SGs of all chemically stressed cell lines tested. Interestingly, about one-fifth of the putative interacting proteins we identified as members of our C9orf72 and SMCR8 interactomes are known SG proteins, which themselves might play a role in targeting of SMCR8 complexes to granules. It is conceivable that SMCR8-C9orf72 SG association is sensitive to cell type, cellular conditions, and levels of interacting proteins as determinants of entry into SGs, and perhaps these factors explain discrepancies between our data and previously published observations.

As reported in other studies, we also presented supporting evidence that C9orf72 protein levels are positively correlated with those of SMCR8 in cultured cells \[[@CR26], [@CR28], [@CR29], [@CR32], [@CR47], [@CR54], [@CR65], [@CR103]\]. Furthermore, we now show that SMCR8 protein expression is reduced in the brains of C9ALS patients compared with unaffected controls (and as also recently noted by \[[@CR25]\]. To date, it has been reported that a small number of proteins, including neurofilament proteins, are differentially expressed in the CSF of ALS and FTD proteins and have been proposed as candidate biomarkers for the C9orf72 mutation \[[@CR116], [@CR117]\]. Whether or not SMCR8 protein can also be an effective CSF or plasma biomarker for C9 expansion patients remains to be determined and is likely contingent upon the development of better α-SMCR8 antibodies.

Conclusions {#Sec15}
===========

In this study we characterized the protein interactome of SMCR8, which binds the protein product of *C9orf72*, the major susceptibility gene for ALS. Using a robust and highly specific protocol, we demonstrated ubiquitination without significant degradation of SMCR8 protein and its association with many components of the ubiquitin-proteasome system. Evidence was presented for localization of endogenous SMCR8 protein to cytoplasmic stress granules, although in several cell lines we failed to reproduce previous observations that C9orf72 protein enters these granules. SMCR8 protein levels were downregulated in whole tissue brain lysates of C9ALS patients compared with unaffected controls, suggesting the potential usefulness for SMCR8 as a biomarker of the disease state.

In addition to ALS and FTD, the *C9orf72* gene expansion mutation has been linked with other neurodegenerative and psychiatric disorders, although etiological roles remain unknown \[[@CR118]--[@CR123]\]. We have shown that SMCR8, whose cellular levels positively correlate with C9orf72 protein expression, associates not only with many factors of protein metabolism and stress granule dynamics, but also with numerous products of genes linked with a range CNS disorders (65/340 in total, Table [2](#Tab2){ref-type="table"}). It is therefore reasonable in future studies to consider a role for SMCR8 in these diverse neuropathologies, perhaps relating to recruitment of the UPS with consequent effects on protein homeostasis.
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**Additional file 1 Fig. S1.** Western blotting of cell line and brain tissue lysates using commercial antibodies against C9orf72, SMCR8, and WDR41 proteins. Antibodies shown are (A) α-C9ORF72-PT (Proteintech Group 22637--1), (B) α-SMCR8-PT (Proteintech 21125--1-AP, (C) α-SMCR8-B (Bethyl Laboratories A304-694A), (D) α-SMCR8-ab186504 (Abcam ab186504), (E) α-SMCR8-ab202283 (Abcam ab202283), (F) α-WDR41-SC (Santa Cruz sc-137923), and (G) α-WDR41-PT (Proteintech 26817--1-AP). Large arrows mark full-length protein products. The small arrows in (F) and (G) mark the presumed minor 45.5 kD WDR41 isoform. Samples were run on NuPAGE 4--12% Bis-Tris Protein gels (Novex) and Western blotting was performed according to \[[@CR81], [@CR82]\]. Molecular weight markers are Novex Sharp Pre-stained Protein Standard. Motor: motor cortex, Occ: occipital cortex, S.C.: spinal cord; sample identifier numbers are also shown. **Fig. S2.** Pie chart of results of DAVID (Database for Annotation, Visualization and Integrated Discovery, \[[@CR83]\]) analyses of KEGG pathways showing selected functional categories for candidate member proteins of the (A) FL-SMCR8 and (B) C9orf72-FL protein interactomes. Percentages of the total number of proteins identified (Tables [S1](#MOESM1){ref-type="media"} and [S2](#MOESM1){ref-type="media"}) for each category are shown within the slices. **Fig. S3.** Phylogenetic multi-sequence alignment of SMCR8 protein sequences for ten species. Alignments were made with Clustal Omega 1.2.1 (EMBL-EBI) followed by BoxShade 3.2 (<http://sourceforge.net/projects/boxshade>). Pink shading marks amino acid residues identical in at least 8 species, while green includes conservative replacements. Lysine residues predicted by MS sequencing to be ubiquitinated are boxed in blue (see Table [S3](#MOESM1){ref-type="media"}). Species shown are: *Homo sapiens*, human; *Pan troglodytes*, chimpanzee; *Canus lupus familiaris*, dog; *Mus musculus*, house mouse; *Rattus norvegicus*, brown rat; *Gallus gallus domesticus*, chicken; *Danio rerio*, zebrafish; *Xenopus tropicalis*, western clawed frog; *Biomphalaria glabrata*, freshwater snail; *Aplysia californica*, California sea hare. **Fig. S4.** Immunofluorescence microscopy evidence for association of SMCR8 protein with cytoplasmic aggregates. (A) V5-tagged SMCR8 does not significantly enter SGs of NaAsO~2~-stressed N2A cells. (B) Overexpression of FLAG-tagged C9orf72 (left) or SMCR8 (right) protein does not induce formation of cytoplasmic granules in neuroblastoma cells. (C) V5-tagged exogenously expressed C9orf72 fails to enter SGs in NaAsO~2~-treated U2OS cells. (D) Endogenous C9orf72 protein speckles observed in unstressed N2A cells are not marked by TIA1, a SG protein. (E) C9orf72 protein detected by the α-C9orf72-PT antibody fails to enter SGs of NaAsO~2~-stressed U2OS cells. (F,G), Endogenous C9orf72 protein detected by the α-C9orf72-SC antibody colocalizes or justaposes with only a minor subset of SGs (marked by TIA1) or PBs (marked by 4-ET) in stressed mouse neuroblastoma N2A cells (see arrows). (H) In NaAsO~2~-stressed 293T cells, endogenous SMCR8 detected by the α-SMCR8-PT antibody colocalizes with granules marked by ORF1p, a protein encoded by LINE-1 retrotransposons \[[@CR81]\]. (I) In NaAsO~2~-stressed human neuroblastoma SK-N-SH cells, endogenous SMCR8 localizes to SGs marked by α-eIF3η antibody. (J) In N2A cells treated with the endoplasmic reticulum stressor thapsigarin, endogenous SMCR8 protein colocalizes to granules marked by HEDLS/EDC4 (detected by α-p70 S6 kinase antibody, \[[@CR77]\]), a component of PBs. (K) In unstressed N2A cells, endogenous SMCR8 localizes in granules with GW142, a PB marker. (L) Exogenously expressed TDP-43 and endogenous SMCR8 proteins do not colocalize in cytoplasmic granules of stressed U2OS cells. (M) SMCR8 rings but is generally excluded from overexpressed GFP-(GA)~50~ dipeptide aggregates. (M) In 293T cells, the α-WDR41-PT antibody detects endogenous protein in or beside a subset granules marked by 4-ET (see arrows). NT: no treatment. Cell nuclei were stained with Hoechst 33342 (right-most panels). Size bars are 10 μm. **Table S1.** The C9orf72 protein interactome determined by mass spectrometry. **Table S2.** The SMCR8 protein interactome determined by mass spectrometry. **Table S3.** Ubiquitinated SMCR8 lysine residues determined by MS sequencing, prediction algorithms, and the comparative phylogenetic analyses of **Fig. S3.Table S4.** Post-mortem brain motor cortex tissue samples used for the analyses of Fig. [5](#Fig5){ref-type="fig"}b,c.
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